| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-06-02 | Roche (Switzerland) Clovis Oncology (USA) | in vitro PCR (Polymerase Chain Reaction) based EGFR companion diagnostic test | non small cell lung cancer | development |
Cancer - Oncology | Development agreement |
| 2011-05-31 | MediGene (Germany) The Johns Hopkins University (USA) | vaccine candidates derived from the AAVLP program | HPV-associated cancer | R&D |
CancerOncology | R&D agreement |
| 2011-05-30 | Sanofi (France) DNDI (Switzerland) | new treatments for nine neglected tropical diseases | This agreement covers nine neglected tropical diseases : kinetoplastid diseases(leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections(lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis,fascioliasis, and schistosomiasis. | R&D |
Infectious diseasesParasitic diseasesTropical diseases | Collaboration agreement |
| 2011-05-26 | Bayer Schering Pharma (Germany) Epitomics (USA) | monoclonal antibody technology | Services |
Services contract | ||
| 2011-05-25 | Rhenovia Pharma (France) Portmann Instruments (Switzerland) | biosimulation services drug optimization technologies | promotion |
CNS diseases | Commercialisation agreement | |
| 2011-05-25 | Evotec (Germany) PsychoGenics (USA) | drug discovery solutions | collaboration |
CNS diseases | Collaboration agreement | |
| 2011-05-25 | Cancer Research UK (UK) Cancer Research Technology (UK) Centella Therapeutics (USA) | CEN-209 | solid tumors | development |
Cancer - Oncology | Development agreement |
| 2011-05-24 | AstraZeneca (UK) Daiichi Sankyo (Japan) | denosumab | bone disorders stemming from bone metastasis | Co-promotion |
Cancer - Oncology | Distribution agreement |
| 2011-05-20 | HRA Pharma (France) ASKA Pharmaceutical (Japan) | ulipristal acetate | uterine fibroids | licensing |
Gynecology - Women's health | Licensing agreement |
| 2011-05-19 | HRA Pharma (France) ASKA Pharmaceutical (Japan) | ellaOne® (ulipristal acetate) | emergency contraception | licensing |
Gynecology - Women's health | Licensing agreement |
| 2011-05-17 | Merck&Co (USA) Roche (Switzerland) | Victrelis® (boceprevir) | Hepatitis C | collaboration co-promotion |
Infectious diseases | Collaboration agreement |
| 2011-05-17 | SuppreMol (Germany) University of Regensburg(Germany) | antibody directed against interleukin 3 (IL-3) | rheumatoid arthritis | licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2011-05-17 | Alliance Pharma (UK) Sanofi Pasteur (France) | ImmuCyst® | non-muscle-invasive bladder cancer | distribution |
Cancer- Oncology | Distribution agreement |
| 2011-05-17 | BiolineRx (Israel) Algen BioPharmaceuticals (Israel) | BL-7030 | rights acquisition |
Cancer - Oncology | Product acquisition | |
| 2011-05-16 | Clavis Pharma (Norway) Translational Therapeutics (USA) | CP-4033 | thyroid cancer - solid tumor | licensing |
Cancer - Oncology | Licensing agreement |
| 2011-05-16 | Sanofi (France) Glenmark Pharmaceuticals (India) | GBR 500 | Crohn’s disease and other inflammatory conditions | licensing |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Licensing agreement |
| 2011-05-16 | Neurosearch (Denmark) Janssen Pharmaceutica (J&J) (USA) | CNS medicines | R&D development commercialisation distribution |
CNS diseases | R&D agreement | |
| 2011-05-16 | Quintiles (USA) Population Genetics Technologies (UK) | genomic testing for drug development | collaboration |
Drug development | Collaboration agreement | |
| 2011-05-11 | Syntaxin (UK) SynCo Bio Partners (The Netherlands) | SXN101959 | acromegaly | manufacturing |
Hormonal diseases - Endocrine diseases - Rare diseases | Production agreement |
| 2011-05-11 | BiolineRx (Israel) Cypress Bioscience (USA) | BL-1020 | schizophrenia | licensing |
Mental diseases - Psychiatric diseases | Establishment of a new subsidiary in the EU |
